|
|
|
|
|
|
|
A conversation with Tony Li, Alexion (AZ Rare Disease)
|
AI could shift clinical supply from periodic forecasting to continuous decisions, linking live signals with execution while protecting quality and patient continuity now.
|
|
|
|
|
|
|
Senior pharma leaders from Pfizer, Bayer, BioNTech and others debunk dual sourcing myths and reveal what separates strategic CDMO partnerships from transactional ones.
|
|
|
|
|
|
By Eshaan Jain, Mphasis
|
AI cannot fix clinical trial supply forecasting when the underlying data is fragmented. Structuring enrollment, inventory, and label data comes first.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
.png){kind=logo}
